Metastatic Basal Cell Carcinoma: Treatment with a potentially best in class Hedgehog Inhibitor, Taladegib (EADV 2023) - Aug 30, 2023 - Abstract #P1003; 1024; Pres time: Oct 11, 2023; 09:00 AM; Location: e-Poster Hall; "Patient was further treated by vismodegib for 12 months followed by Cemiplimab. For the first time we report here that mBCC patients who were refractory to current standard of care treatments responded to taladegib with a duration of response of around one year with fewer and manageable adverse effects."
IO biomarker • Metastases • Alopecia • Basal Cell Carcinoma • Fatigue • Non-melanoma Skin Cancer • Oncology • Pulmonary Disease • PTCH1
|
|
Christopher Vaughn1; Srikanth Pendyala*2; Sohee Kim2; Anita Difrancesco2; Miguel Del Rios2; John Hood2; David Hong3
|